The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.
about
Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usageMultilocus sequence typing compared to pulsed-field gel electrophoresis for molecular typing of Pseudomonas aeruginosaStrategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptidesSubstrate Specificity within a Family of Outer Membrane Carboxylate ChannelsIn-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in SingaporeA large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition.Surveillance of antimicrobial resistance among clinical isolates recovered from a tertiary care hospital in Al Qassim, Saudi Arabia.Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittiiMolecular epidemiology of a Pseudomonas aeruginosa hospital outbreak driven by a contaminated disinfectant-soap dispenser.Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agentsRecommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase in Acinetobacter baumanniiScreening for Acinetobacter baumannii colonization by use of sponges.Antimicrobial Resistance in Pseudomonas sp. Causing Infections in Trauma Patients: A 6 Year Experience from a South Asian Country.The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.Pseudomonas aeruginosa: resistance to the maxPrevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in EgyptClinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.The rising problem of antimicrobial resistance in the intensive care unit.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremiaTigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complexRole of the Outer Membrane Protein OprD2 in Carbapenem-Resistance Mechanisms of Pseudomonas aeruginosaDuration of hospital admission and the need for empirical antipseudomonal therapy.Novel approaches to developing new antibiotics for bacterial infections.Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.Pseudomonas aeruginosa infection among cystic fibrosis and ICU patients in the referral children medical hospital in Tehran, Iran.Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital.Review on the Antimicrobial Resistance of Pathogens from Tracheal and Endotracheal Aspirates of Patients with Clinical Manifestations of Pneumonia in Bacolod City in 2013Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatmentMultidrug-resistant gram-negative bacteria among patients who require chronic hemodialysisNatural history of multidrug-resistant Acinetobacter baumannii carriage in intensive care unitsNetwork-assisted investigation of virulence and antibiotic-resistance systems in Pseudomonas aeruginosaColonization pressure as a risk factor for colonization by multiresistant Acinetobacter spp and carbapenem-resistant Pseudomonas aeruginosa in an intensive care unitAcinetobacter baumannii: an emerging multidrug-resistant threat.In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.Clinical and Economic Evaluation of Multidrug-Resistant Acinetobacter baumannii Colonization in the Intensive Care Unit
P2860
Q21560993-F6A93097-AFC5-49F0-B679-F1A5DBF961CBQ24681877-53D02E49-10EC-41F6-A2E8-496294BAC9BFQ26861137-FDD8C619-4A9A-4E06-BE1E-08A1611B4D78Q27676856-7E75678D-67F3-485D-81F5-DA8779BC5A7BQ28740868-82F8D7C5-2B1E-41C1-B4B7-89252F370A1AQ31034219-6E970783-4226-49DF-BBC6-53B6D1FE1CC1Q33690429-94302987-2812-4325-844D-4E184CFA5FF6Q33798301-E4ACF79F-FC51-44FC-926A-5C8F6809F8C2Q33832119-9B2778B2-1217-4DD6-95AD-21ADEFF8549AQ33903912-76F59C63-1575-4642-A8B1-6C7240090B97Q34165319-93854BF6-3BA9-4812-BB48-BF6F5C1BE347Q34483646-D2D18B15-55FF-4D96-BCD1-DFC38ACC8404Q34487407-58289A2B-53F3-4AB5-B87A-2DA0D216498CQ34699065-D1BB5B29-E414-416E-BC6C-1B6F6527C970Q34766027-12663F2E-10D7-43A9-BF9E-9FE780E147A2Q34984415-F5CECD44-44D0-4706-B9EF-5B829FCB272FQ35084559-F5E46495-270F-4EA8-BCF8-1D2B34B78461Q35195783-3F85D773-D772-4C12-9917-E77C1BED0A0DQ35364351-DD5D2E73-1D84-4D38-B55F-2291616B9A9EQ35595833-770CC805-24B7-4AAC-B790-A5336039A121Q35598403-7E7C2CA4-6EB3-4A80-BC44-37AB400B6704Q35647670-67EE30F6-53CF-4F4C-8D2D-947D25D6E240Q35661920-9A34CD77-B1A6-4A2E-A094-B8D5F494FC8EQ36096472-92496C23-D5FA-4DEB-9E77-3262A7E5C652Q36126904-519ACC24-1E3E-4A3F-9747-DD05DB8B5E57Q36171313-D830DD28-6D28-484E-A984-B8E4AFA8353EQ36358643-753E58AE-8B8B-4168-919B-6158893792A7Q36405521-500CEB6D-2068-4824-B94E-77F536EEB71AQ36478473-F9F4CEB6-3417-4F81-BFD2-04CC36BFD3BCQ36491060-866E966C-507A-4C19-B8E5-A15881F10DCEQ36556699-F9CC7118-35D5-4383-ADF2-48590F4156C7Q36646107-AC2516DE-BC15-445B-AE14-1674A46EC047Q36662088-E65EAE39-A516-4061-99D7-646016DA7AE1Q36819829-74D18D1D-8258-4A59-BEB1-F803FAAD8D95Q36914772-3971CAA1-E37F-4E38-9FD2-D5C705831881Q37119067-2F8DC2BB-AFE6-47E5-9A00-9FDC3012AE9EQ37202840-23A189F3-F8F8-459C-B9A9-6F66118F1103Q37220041-4DFDEAA2-BD21-4F46-901E-69508282E2D5Q37247751-2665D45E-FF83-4118-9C1A-9BE2AB3D00A6Q37306643-460B3199-CD33-4BAE-BC1A-11A626ACFABA
P2860
The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The epidemiological profile of ...... osa and Acinetobacter species.
@ast
The epidemiological profile of ...... osa and Acinetobacter species.
@en
type
label
The epidemiological profile of ...... osa and Acinetobacter species.
@ast
The epidemiological profile of ...... osa and Acinetobacter species.
@en
prefLabel
The epidemiological profile of ...... osa and Acinetobacter species.
@ast
The epidemiological profile of ...... osa and Acinetobacter species.
@en
P921
P356
P1476
The epidemiological profile of ...... osa and Acinetobacter species.
@en
P356
10.1086/504476
P407
P478
43 Suppl 2
P577
2006-09-01T00:00:00Z